EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 521 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Invasive Lobular Carcinoma Is Invisible On Mammograms, Isn’t A Lump April 4, 2019 Woman Helps Students With Special Needs Achieve Success After Graduation December 23, 2021 Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in... April 8, 2022 Immune Pathways Help Identify Patients with Cancer and HIV Most Likely... March 9, 2026 Load more HOT NEWS Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women... Bariatric Surgery May Reduce the Risk of Some Common Cancers Embracing Lung Cancer Survivorship Mom Gives ‘Elf On The Shelf’ A Wheelchair For Daughter With...
